These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34067301)

  • 1. Lantox-The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review.
    Dressler D; Pan L; Su J; Teng F; Jin L
    Toxins (Basel); 2021 May; 13(6):. PubMed ID: 34067301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing lanbotulinumtoxinA (Hengli
    Pan L; Bigalke H; Kopp B; Jin L; Dressler D
    J Neural Transm (Vienna); 2019 Dec; 126(12):1625-1629. PubMed ID: 31707463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Botulinum toxin--the all-rounder in medicine].
    Schröder AS; Fietzek UM; Pavicic T; Stehr M; Baumann AC; Ruzicka T; Heinen F
    MMW Fortschr Med; 2011 Jan; 153(4):33-9; quiz 40. PubMed ID: 22165615
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study.
    Wein T; Jog M; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
    Can J Neurol Sci; 2019 Nov; 46(6):742-752. PubMed ID: 31256770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
    Hubble J; Schwab J; Hubert C; Abbott CC
    Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey.
    Smania N; Colosimo C; Bentivoglio AR; Sandrini G; Picelli A
    Funct Neurol; 2013; 28(4):253-8. PubMed ID: 24598392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
    Duarte GS; Castelão M; Rodrigues FB; Marques RE; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD004314. PubMed ID: 27782297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment.
    Jog M; Wein T; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
    Can J Neurol Sci; 2016 Sep; 43(5):687-96. PubMed ID: 27430524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Botulinum toxin type A in children: evaluation of indications with a review of the literature].
    Bertrand H; Forin V
    Ann Readapt Med Phys; 2003 Jul; 46(6):346-52. PubMed ID: 12928142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of botulinum toxin in neurological indications.
    Ward AB; Molenaers G; Colosimo C; Berardelli A
    Eur J Neurol; 2006 Dec; 13 Suppl 4():20-6. PubMed ID: 17112346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine use of Xeomin in patients previously treated with Botox: long term results.
    Dressler D
    Eur J Neurol; 2009 Dec; 16 Suppl 2():2-5. PubMed ID: 20002739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Indications and management of botulinum toxin].
    Singer C
    Rev Neurol; 1999 Jul 16-31; 29(2):157-62. PubMed ID: 10528331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type A therapy for hemifacial spasm.
    Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004899. PubMed ID: 15674968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
    Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
    Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Injection-Guiding Techniques on the Effectiveness of Botulinum Toxin for the Treatment of Focal Spasticity and Dystonia: A Systematic Review.
    Grigoriu AI; Dinomais M; Rémy-Néris O; Brochard S
    Arch Phys Med Rehabil; 2015 Nov; 96(11):2067-78.e1. PubMed ID: 25982240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.
    Lukban MB; Rosales RL; Dressler D
    J Neural Transm (Vienna); 2009 Mar; 116(3):319-31. PubMed ID: 19142573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin in motor disorders.
    Bentivoglio AR; Albanese A
    Curr Opin Neurol; 1999 Aug; 12(4):447-56. PubMed ID: 10555834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, randomised, crossover trial of two botulinum toxin type a in patients with spasticity.
    Guarany FC; Picon PD; Guarany NR; dos Santos AC; Chiella BP; Barone CR; Fendt LC; Schestatsky P
    PLoS One; 2013; 8(2):e56479. PubMed ID: 23468866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of botulinum toxin A in children with cerebral palsy in Gross Motor Function Classification System levels IV and V: a systematic review.
    Pin TW; Elmasry J; Lewis J
    Dev Med Child Neurol; 2013 Apr; 55(4):304-13. PubMed ID: 23095013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.